Clinical Trial Update | Nivolumab plus Relatlimab for advanced melanoma fail to reach OS threshold despite PFS improvement
25 Apr, 2023 | 14:25h | UTCOverall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma – NEJM Evidence
Original Study: Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma – New England Journal of Medicine
Commentary on Twitter
Original Article: “Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma,” by Georgina V. Long, MD, PhD, et al. https://t.co/g5N1AYQV1I#OncoAlert #Melanoma
— NEJM Evidence (@NEJMEvidence) April 19, 2023